These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35255986)

  • 21. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
    Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
    Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.
    Kelly LP; Carvey PM; Keshavarzian A; Shannon KM; Shaikh M; Bakay RA; Kordower JH
    Mov Disord; 2014 Jul; 29(8):999-1009. PubMed ID: 24898698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic Effects of Milk-Derived Exosomes and Galactose on
    Melnik BC
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
    Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity.
    Stoll AC; Sortwell CE
    Neurobiol Dis; 2022 Sep; 171():105804. PubMed ID: 35764290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway.
    Renaud J; Bassareo V; Beaulieu J; Pinna A; Schlich M; Lavoie C; Murtas D; Simola N; Martinoli MG
    Neurobiol Aging; 2018 Sep; 69():117-128. PubMed ID: 29890391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice.
    Karikari AA; McFleder RL; Ribechini E; Blum R; Bruttel V; Knorr S; Gehmeyr M; Volkmann J; Brotchie JM; Ahsan F; Haack B; Monoranu CM; Keber U; Yeghiazaryan R; Pagenstecher A; Heckel T; Bischler T; Wischhusen J; Koprich JB; Lutz MB; Ip CW
    Brain Behav Immun; 2022 Mar; 101():194-210. PubMed ID: 35032575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease.
    Brembati V; Faustini G; Longhena F; Outeiro TF; Bellucci A
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
    Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
    J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP.
    Hansen C; Björklund T; Petit GH; Lundblad M; Murmu RP; Brundin P; Li JY
    Neurobiol Dis; 2013 Aug; 56():145-55. PubMed ID: 23643841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-Dependent Alpha-Synuclein Accumulation and Phosphorylation in the Enteric Nervous System in a Transgenic Mouse Model of Parkinson's Disease.
    Zhong CB; Chen QQ; Haikal C; Li W; Svanbergsson A; Diepenbroek M; Li JY
    Neurosci Bull; 2017 Oct; 33(5):483-492. PubMed ID: 28924920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fine Particulate Matter Triggers α-Synuclein Fibrillization and Parkinson-like Neurodegeneration.
    Yuan X; Yang Y; Liu C; Tian Y; Xia D; Liu Z; Pan L; Xiong M; Xiong J; Meng L; Zhang Z; Ye K; Jiang H; Zhang Z
    Mov Disord; 2022 Sep; 37(9):1817-1830. PubMed ID: 36054165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
    Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
    Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1.
    Lin X; Parisiadou L; Sgobio C; Liu G; Yu J; Sun L; Shim H; Gu XL; Luo J; Long CX; Ding J; Mateo Y; Sullivan PH; Wu LG; Goldstein DS; Lovinger D; Cai H
    J Neurosci; 2012 Jul; 32(27):9248-64. PubMed ID: 22764233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease.
    Tan Y; Sgobio C; Arzberger T; Machleid F; Tang Q; Findeis E; Tost J; Chakroun T; Gao P; Höllerhage M; Bötzel K; Herms J; Höglinger G; Koeglsperger T
    Acta Neuropathol; 2020 Feb; 139(2):319-345. PubMed ID: 31768670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.